PLASMA CYTOKINE MEASUREMENTS AUGMENT PROGNOSTIC SCORES AS INDICATORS OF OUTCOME IN PATIENTS WITH SEVERE SEPSIS

Despite recent advances in the prospective identification of the patient with sepsis who may benefit from anti-inflammatory or antithrombotic therapies, successful treatment regimens have been fairly modest. We have explored whether determination of several proinflammatory cytokine or mediator concentrations can complement physiologic scoring systems to identify patients with severe sepsis who will survive or expire within 28 days. The design of the study included an exploratory analysis performed in conjunction with a prospective, randomized, double-blind, placebo-controlled, multicenter, clinical trial and involved 33 academic institutions in the United States. One hundred twenty-four patients with severe sepsis with or without septic shock were included in this analysis. Blood samples were obtained at baseline and on days 1 through 4, and were evaluated for proinflammatory and anti-inflammatory cytokine concentrations, as well as for procalcitonin and total protein C levels. Baseline concentrations and changes in the concentrations of these mediators were evaluated in relationship to the Acute Physiology and Chronic Health Evaluation (APACHE) II and multiple organ dysfunction (MOD) scores, and 28-day all-cause mortality. Using univariate logistic regression analyses, APACHE II and MOD scores, age (but not gender), and baseline plasma interleukin (IL)-6 and soluble tumor necrosis factor receptor (sTNFR) 1 (log transformed) concentrations were all predictive of increased 28-day all-cause mortality (P < 0.01). Baseline total protein C, IL-8, IL-10, TNF-α, and procalcitonin concentrations, and the change in plasma cytokine concentrations from baseline over the initial 4 days were not useful in predicting outcome. Selected baseline proinflammatory cytokine concentrations and APACHE II score were correlated (P < 0.01). IL-6 concentration is a strong candidate for predicting clinical outcome in patients with severe sepsis alone, or when combined with the APACHE II or MOD scores. The potential usefulness of the combination of cytokine measurements and prognostic scores to identify patients who may benefit from treatment with anti-inflammatory or antithrombotic therapies should be further evaluated.

[1]  Alain Cariou,et al.  Universal changes in biomarkers of coagulation and inflammation occur in patients with severe sepsis, regardless of causative micro-organism [ISRCTN74215569] , 2004, Critical care.

[2]  S. Opal,et al.  Recombinant human platelet-activating factor acetylhydrolase for treatment of severe sepsis: Results of a phase III, multicenter, randomized, double-blind, placebo-controlled, clinical trial* , 2004, Critical care medicine.

[3]  Thomas A. Buckley,et al.  Validation of the multiple organ dysfunction (MOD) score in critically ill medical and surgical patients , 2003, Intensive Care Medicine.

[4]  V. Pettilä,et al.  PREDICTIVE VALUE OF MONOCYTE HISTOCOMPATIBILITY LEUKOCYTE ANTIGEN‐DR EXPRESSION AND PLASMA INTERLEUKIN‐4 AND ‐10 LEVELS IN CRITICALLY ILL PATIENTS WITH SEPSIS , 2003, Shock.

[5]  S. Opal,et al.  Recombinant platelet-activating factor acetylhydrolase to prevent acute respiratory distress syndrome and mortality in severe sepsis: Phase IIb, multicenter, randomized, placebo-controlled, clinical trial. , 2003, Critical care medicine.

[6]  L. Pedersen,et al.  Mediators of inflammation correlate with microalbuminuria in patients with non‐Hodgkin's lymphoma , 2003, British journal of haematology.

[7]  M. Freedman,et al.  Monocyte‐derived cytokines in multiple sclerosis , 2003, Clinical and experimental immunology.

[8]  G. Slotman.  Prospectively validated prediction of physiologic variables and organ failure in septic patients: The Systemic Mediator Associated Response Test (SMART) , 2002, Critical care medicine.

[9]  L. Moldawer,et al.  SEPSIS SYNDROMES: UNDERSTANDING THE ROLE OF INNATE AND ACQUIRED IMMUNITY , 2001, Shock.

[10]  J Ean,et al.  Efficacy and safety of recombinant human activated protein C for severe sepsis. , 2001, The New England journal of medicine.

[11]  T. Butler,et al.  Lenercept (p55 tumor necrosis factor receptor fusion protein) in severe sepsis and early septic shock: A randomized, double-blind, placebo-controlled, multicenter phase III trial with 1,342 patients , 2001, Critical care medicine.

[12]  G. Slotman.  Prospectively validated prediction of organ failure and hypotension in patients with septic shock: the Systemic Mediator Associated Response Test (SMART). , 2000, Shock.

[13]  J. Köhl,et al.  Discrimination of sepsis and systemic inflammatory response syndrome by determination of circulating plasma concentrations of procalcitonin, protein complement 3a, and interleukin-6 , 2000, Critical care medicine.

[14]  U. Janssens,et al.  Evaluation of the SOFA score: a single-center experience of a medical intensive care unit in 303 consecutive patients with predominantly cardiovascular disorders , 2000, Intensive Care Medicine.

[15]  José A Fernández,et al.  Prognostic value of protein C concentrations in neutropenic patients at high risk of severe septic complications , 2000, Critical care medicine.

[16]  J. Vincent,et al.  Scoring systems for assessing organ dysfunction and survival. , 2000, Critical care clinics.

[17]  J. Renart,et al.  Predictive Value of Nuclear Factor κB Activity and Plasma Cytokine Levels in Patients with Sepsis , 2000, Infection and Immunity.

[18]  Douglas M. Call,et al.  Immunopathologic Alterations in Murine Models of Sepsis of Increasing Severity , 1999, Infection and Immunity.

[19]  T. Yamashita,et al.  Change in the ratio of interleukin-6 to interleukin-10 predicts a poor outcome in patients with systemic inflammatory response syndrome. , 1999, Critical care medicine.

[20]  G. Lipowsky,et al.  Interleukin-1 receptor antagonist and interleukin-6 for early diagnosis of neonatal sepsis 2 days before clinical manifestation , 1998, The Lancet.

[21]  R. Westendorp,et al.  Anti-inflammatory cytokine profile and mortality in febrile patients , 1998, The Lancet.

[22]  P. Isomäki,et al.  Pro- and anti-inflammatory cytokines in rheumatoid arthritis. , 1997, Annals of medicine.

[23]  T. van der Poll,et al.  Effects of IL-10 on systemic inflammatory responses during sublethal primate endotoxemia. , 1997, Journal of immunology.

[24]  J. Puyana,et al.  A membrane TNF-alpha/TNFR ratio correlates to MODS score and mortality. , 1996, Shock.

[25]  K. Werdan,et al.  Early prediction of outcome in score-identified, postcardiac surgical patients at high risk for sepsis, using soluble tumor necrosis factor receptor-p55 concentrations. , 1996, Critical care medicine.

[26]  M. Howard,et al.  Interleukin 10 protects mice from lethal endotoxemia , 1993, The Journal of experimental medicine.

[27]  A. Costarino,et al.  Correlation of plasma cytokine elevations with mortality rate in children with sepsis. , 1992, The Journal of pediatrics.

[28]  W. Knaus,et al.  The APACHE III prognostic system. Risk prediction of hospital mortality for critically ill hospitalized adults. , 1991, Chest.

[29]  E. Draper,et al.  APACHE II: A severity of disease classification system , 1985, Critical care medicine.

[30]  C. Gogos,et al.  Pro- versus anti-inflammatory cytokine profile in patients with severe sepsis: a marker for prognosis and future therapeutic options. , 2000, The Journal of infectious diseases.

[31]  B. Hazenberg,et al.  Patterns of cytokines, plasma endotoxin, and acute phase proteins during the treatment of severe sepsis in humans. , 1991, Progress in clinical and biological research.